ScreenerHero

WVE Wave Life Sciences, Inc.

NAS · US · Healthcare · Biotechnology · wavelifesciences.com
3.540USD+0.57%Mkt Cap: 697.55M $P/E: —

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap697.55M USD
Enterprise Value246.60M USD
Revenue (TTM)65.37M USD
Gross Profit-132.05M USD
Net Income (TTM)-204.38M USD
Revenue/Share0.35 USD
Last Price3.540 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees317
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.04
PEG—
EV/EBITDA-1.15
EV/Revenue3.77
P/S10.61
P/B1.50
EPS (TTM)-1.08
EPS (Forward)-1.16
52W Range
3.4301% of range21.73
52W High21.73 USD
52W Low3.430 USD
Profitability
Gross Margin-202.00%
Oper. Margin-3248.33%
EBITDA Margin0.00%
Profit Margin-478.33%
ROE-39.43%
ROA-32.01%
Growth
Revenue Growth-73.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-187.49M USD
CapEx (TTM)718.00K USD
FCF Margin-197.00%
FCF Yield-18.46%
Net Debt-447.01M USD
Net Debt/EBITDA2.08
Balance Sheet
Debt/Equity0.03
Current Ratio9.99
Quick Ratio9.67
Book Value/Sh2.35 USD
Cash/Share2.49 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)18.06 USD
Upside (mean)+410.0%
Target Range10.00 USD – 42.00 USD
10.00+410.0% to mean42.00
# Analysts18
Ownership
Shares Out.197.05M
Float94.57M
Insiders15.50%
Institutions85.37%
Short Interest
Short Ratio5.5d
Short % Float11.04%
Short % Out.8.95%
Shares Short17.64M
Short (prev mo.)16.20M
Technical
SMA 504.923 (-28.1%)
SMA 2008.626 (-59.0%)
Beta-1.43
S&P 52W Chg15.78%
Avg Vol (30d)3.45M
Avg Vol (10d)3.70M
Technical Indicators
RSI (14)25.7
MACD-0.4094
MACD Signal-0.3990
MACD Hist.-0.0104
BB Upper5.098 USD
BB Middle4.138 USD
BB Lower3.177 USD
BB Width46.44%
ATR (14)0.2433 USD
Vol Ratio (20d)0.86x